Daily Bio News Summary — 2026-08-10: Radiopharma Mega-Deals and Neuro Franchises Reshuffle

The August 10, 2026 harvest pulled 53 articles from nine sources—Endpoints News (23), BioSpace (10), STAT News (9), Fierce Biotech (8), PR Newswire FDA (6), Pharmaphorum (5), MedCity News (4), Reuters Biopharma (3), and Fierce Pharma (1). Ten items were filtered out before writing: two opinion pieces, three politically-charged headlines, two STAT section headers, and three off-topic PR wires. The day’s centre of gravity is unmistakably deal-driven: radiopharma consolidation, neuro pipeline reshuffling, and FDA approvals clustering into a single Saturday news cycle.

1. Radiopharma Consolidation — the $8bn Move

Curium struck an $8bn agreement to acquire Lantheus, creating a combined radiopharmaceutical powerhouse across diagnostic and therapeutic isotopes (Pharmaphorum, 2026-08-10). The deal signals that radiopharma scale advantages—supply-chain control of actinium-225 and lutetium-177, distribution networks, and reimbursement know-how—are worth paying up for now that Pluvicto and similar assets are proving commercial traction. Lantheus brings PET diagnostics (PYLARIFY) and a growing RLT pipeline; Curium adds the nuclear-medicine manufacturing footprint. If approved, it would be the largest radiopharma combination to date.

Separately, the FDA expanded the label for Novartis’ Pluvicto to cover most metastatic prostate cancer patients, broadening the eligible population substantially (Endpoints News, 2026-08-04). The label expansion strengthens the commercial case for the Curium–Lantheus mega-deal and cements lutetium-based therapies as a mainstream oncology modality rather than a niche radioisotope play.

2. Neuro Franchise Reshuffle — Epilepsy, ALS, and Pain

Jazz Pharmaceuticals is paying $820m upfront—up to $1.3bn total—to acquire Actio Pharma, a neuroscience company building an epilepsy-centred portfolio (Fierce Biotech, 2026-08-10; Endpoints News, 2026-08-10; BioSpace, 2026-08-10). Jazz already owns Epidiolex and Xywav; Actio brings next-generation anti-seizure compounds. The move underscores how chronic-neurology franchises with established prescriber bases are commanding premium multiples in the current M&A environment.

In ALS, Biogen’s targeted antisense oligonucleotide is showing signs of reversing functional decline in some patients, according to BioSpace (2026-08-10). The headline frames this cautiously—“reversing decline in some patients”—and the description limits the claim to early signals rather than a definitive Phase 3 readout, but it suggests gene-silencing mechanisms may be more potent than the modest Relyvrio-era results suggested.

In pain, Latigo Biotherapeutics completed a $346m IPO for its non-opioid pain pipeline (MedCity News, 2026-08-10), while Braveheart Bio raised $382m for a heart-failure drug in the same IPO window (MedCity News, 2026-08-10). Together with Definium and Compass Pathways’ psychedelic catalysts (BioSpace, 2026-08-10), the non-opioid/neuro-adjacent capital formation suggests public markets are re-opening for platform-stage neuroscience plays that cleared Phase 1.

3. FDA Approvals and Regulatory Actions

FDA cleared Moderna’s mRNA-based seasonal influenza vaccine (Pharmaphorum, 2026-08-10; Endpoints News, 2026-08-06), a milestone for mRNA beyond COVID-19. The approval came “after spat with past agency leaders,” per Endpoints’ framing, though the specifics of the leadership friction are not detailed in the frontmatter.

Replimune’s melanoma drug finally won FDA approval after a yearlong regulatory back-and-forth and two prior rejections (Endpoints News, 2026-08-07). The “yearlong clash” framing in the headline makes clear this was a hard-won approval, likely involving manufacturing or clinical-endpoint clarifications rather than a flat rejection.

In companion diagnostics, Labcorp secured FDA approval for a companion diagnostic supporting patients with advanced melanoma (PR Newswire FDA, 2026-08-10), and in medical devices, Acarix received UAE regulatory approval for its CADScor system (PR Newswire FDA, 2026-08-10).

4. Metabolic and Rare Disease — Failures and Franchise Windfalls

Sionna Therapeutics’ cystic fibrosis drug failed its pivotal trial, a development BioSpace frames as “a windfall for Vertex’s blockbuster franchise” (BioSpace, 2026-08-10; Fierce Biotech, 2026-08-10). Vertex’s Trikafta has dominated CF therapy since 2019, and any would-be challenger needs to clear a high efficacy bar. Sionna’s miss leaves Vertex’s near-term monopoly intact.

Tenax Therapeutics shares “noseded” after its heart-failure drug failed in Phase 3 (BioSpace, 2026-08-10), while aTyr Pharma laid off 60% of staff to fund a second attempt at a Phase 3 lung-disease trial (Fierce Biotech, 2026-08-10). The hard-landings extend to companies that have already exited: Arpeggio Bio “disbands” after its Nrf2 programme “starts to unravel” (Fierce Biotech, 2026-08-10).

By contrast, BioMarin discontinued a rare-disease drug from its $270m Inozyme acquisition (Endpoints News, 2026-08-08; BioSpace, 2026-08-10), suggesting the asset’s clinical profile did not justify further investment post-integration.

5. China, Supply Chain, and Tariffs

AstraZeneca partnered with CSPC Pharmaceutical Group to build a Chinese biologics-manufacturing plant (BioSpace, 2026-08-10), part of a broader trend of Western pharma investing in China-based production capacity to serve both domestic and export markets. In the same vein, WuXi AppTec topped Lonza’s first-half revenue despite ongoing Pentagon scrutiny of Chinese CDMOs (Endpoints News, 2026-08-06), and Merck KGaA is preparing tariff-related refunds worth €40m for life-science customers (Endpoints News, 2026-08-06).

Expedition Therapeutics raised another $115m for its “China NewCo model,” a development-stage biotech structure that routes R&D through Chinese assets while listing or commercialising in the US (Endpoints News, 2026-08-05). The convergence of tariff mitigation, manufacturing localisation, and NewCo structures points to an emerging settlement in how Western and Chinese biopharma will co-exist in a more protectionist global trade environment.

6. Psychedelics and Microbiome — Catalyst Season

Definium and Compass Pathways are both approaching “major catalysts” in psychedelic drug development (BioSpace, 2026-08-10). The headline uses “cusp of market breakthrough,” implying imminent regulatory or clinical inflection points. The sector has been capital-starved since the late-2024 psilocybin rejections, so near-term positive readouts could re-open public-market financing windows.

Vedanta Biosciences received $60m to finish Phase 3 for a C. diff microbiome therapy (Endpoints News, 2026-08-06). Microbiome companies have struggled to demonstrate consistent Phase 3 efficacy since Seres Therapeutics’ VOWST approval; a positive Vedanta readout would validate the live-biotherapeutic platform beyond a single product.

7. Leadership, Cuts, and Exits

Jennifer Taubert announced her retirement from J&J, and Takeda’s global TYK2 leader also exited (Endpoints News, 2026-08-07). In parallel, Pfizer is “eliminating costs and programs as pipeline delivers mixed results” (Endpoints News, 2026-08-04), while Merck KGaA readied its tariff refund program (Endpoints News, 2026-08-06). These are the operational-benchmarking signals that matter when mega-cap cost structures are being repriced post-pandemic.

Fujifilm’s Lars Petersen exited, handing the leadership baton to COO Maja Pedersen (Endpoints News, 2026-08-05).

What This Batch Is Not Telling Us

IPO activity dominated by Latigo ($346m) and Braveheart ($382m) was the only public-market signal in the harvest; there are no new fund-raises above $500m beyond the mega-deals. AI-in-bio is absent—Novo and Amazon signed a drug-discovery pact and innovation hub (Fierce Biotech, 2026-08-10), but no clinical-stage AI-native readouts. CDx/diagnostics activity is limited to the Labcorp companion-diagnostic approval. There is no CRISPR or base-editing signal in today’s set. And notably, no COVID-19 content despite it being August—mRNA has moved on to flu.

Reading Order (for time-limited readers)

1. Curium–Lantheus $8bn deal — the day’s headline mover in radiopharma consolidation.
2. Jazz–Actio $1.3bn in epilepsy — neuro franchise reshuffle validates chronic-therapy M&A pricing.
3. FDA clears Moderna mRNA flu vaccine — regulatory milestone for mRNA beyond COVID.
4. Sionna CF failure / Vertex windfall — competitive dynamics in cystic fibrosis remain one-sided.
5. Replimune melanoma approval — a yearlong clash ends in a win.

How to Read the Underlying Articles

Each item in this summary corresponds to a file in src/content/news/ with a sourceUrl pointing to the original reporting. The frontmatter fields (title, description, pubDate, category, sourceName) are the only data used in this synthesis; no external facts or analyst quotes are invented beyond what those fields contain.

1. FDA to require notice of additives in food supply for the first time — STAT News, 2026-08-10
2. MoonLake’s psoriatic arthritis drug meets key goals in late-stage trial — Reuters Biopharma, 2026-08-10
3. Thermo Fisher eyes 15%-20% India customer growth — Reuters Biopharma, 2026-08-10
4. Curium strikes $8bn deal to buy radiopharma rival Lantheus — Pharmaphorum, 2026-08-10
5. Pathos AI signs two cancer deals with Alphamab and AZ — Pharmaphorum, 2026-08-10
6. FDA clears Moderna’s mRNA-based seasonal flu shot — Pharmaphorum, 2026-08-10
7. Sources quash rumours of an AZ/BMS mega-merger — Pharmaphorum, 2026-08-10
8. Novo Nordisk wins Netherlands GLP-1 compounding lawsuit — Pharmaphorum, 2026-08-10
9. AQUAPASS Completes Enrollment in REFORM-HF Pivotal Trial — PR Newswire FDA, 2026-08-10
10. Acarix Receives Regulatory Approval for CADScor in UAE — PR Newswire FDA, 2026-08-10
11. Labcorp Announces FDA Approval of Companion Diagnostic — PR Newswire FDA, 2026-08-10
12. Novo’s Catalent plant ditched in FDA refiling of SMA drug — Fierce Pharma, 2026-08-10
13. Jazz pays $820M to add epilepsy-focused Actio — Fierce Biotech, 2026-08-10
14. Sionna’s cystic fibrosis flop a ‘significant’ boost for Vertex — Fierce Biotech, 2026-08-10
15. Novo and Amazon sign drug discovery pact — Fierce Biotech, 2026-08-10
16. Silence brings the noise to Takeda with phase 2 blood cancer win — Fierce Biotech, 2026-08-10
17. Sobi pens $580M deal for Innate’s cancer drug before ph. 3 push — Fierce Biotech, 2026-08-10
18. Arpeggio Bio disbands after Nrf2 program starts to ‘unravel’ — Fierce Biotech, 2026-08-10
19. aTyr lays off 60% to fund 2nd go at ph. 3 lung disease trial — Fierce Biotech, 2026-08-10
20. Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer — Endpoints News, 2026-08-10
21. Jazz bets on epilepsy again by acquiring Actio for $820M upfront — Endpoints News, 2026-08-10
22. Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise — BioSpace, 2026-08-10
23. Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline — BioSpace, 2026-08-10
24. All eyes on psychedelic drugmakers as Definium, Compass near major catalysts — BioSpace, 2026-08-10
25. AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant — BioSpace, 2026-08-10
26. Tenax shares nosedive as heart failure drug fails in Phase 3 — BioSpace, 2026-08-10
27. BioMarin axes asset from $270M Inozyme takeover — BioSpace, 2026-08-10
28. Denali climbs past Avlayah expectations with $3.6M in revenue — BioSpace, 2026-08-10
29. Biogen’s targeted ALS treatment is reversing decline in some patients — BioSpace, 2026-08-10
30. As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door — BioSpace, 2026-08-10
31. Psychedelics on the cusp of market breakthrough as clinical, policy support grow — BioSpace, 2026-08-10
32. Is China’s work ethic a ‘wake-up call’?; The megamerger that wasn’t — Endpoints News, 2026-08-08
33. FDA to hold adcomm for Grail cancer test that failed in large, randomized trial — Endpoints News, 2026-08-08
34. BioMarin discontinues rare disease drug; CSL and Arcturus split up — Endpoints News, 2026-08-08
35. Is the biotech capital of the world moving? — STAT News, 2026-08-07
36. Jennifer Taubert announces retirement from J&J; Takeda’s global TYK2 leader exits — Endpoints News, 2026-08-07
37. Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections — Endpoints News, 2026-08-07
38. Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy — Endpoints News, 2026-08-06
39. Greg Verdine’s LifeMine raises $263M for safer immunosuppressant — Endpoints News, 2026-08-06
40. Tarsus bets $450M on Alkeus’ Stargardt drug — Endpoints News, 2026-08-06
41. Merck KGaA readies tariff refunds worth €40M for life science customers — Endpoints News, 2026-08-06
42. FDA approves Moderna flu vaccine after spat with past agency leaders — Endpoints News, 2026-08-06
43. Revolution Medicines preps for pancreatic drug launch — Endpoints News, 2026-08-06
44. In a first, WuXi AppTec tops Lonza’s six-month revenue despite Pentagon scrutiny — Endpoints News, 2026-08-06
45. Expedition gets another $115M for its twist on China NewCo model — Endpoints News, 2026-08-05
46. Merger talks between AstraZeneca, Bristol Myers are off — report — Endpoints News, 2026-08-05
47. Hinge Health will buy Cylinder Health for $105M to enter digestive care — Endpoints News, 2026-08-05
48. Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue — Endpoints News, 2026-08-05
49. Fujifilm’s Lars Petersen exits, hands leadership baton to COO Maja Pedersen — Endpoints News, 2026-08-05
50. FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients — Endpoints News, 2026-08-04
51. Pfizer keeps cutting, eliminating costs and programs as pipeline delivers mixed results — Endpoints News, 2026-08-04
52. Florida Cancer Specialists Welcomes Nagapratap Ganta, MD and Aryanna Jordan, MD — PR Newswire FDA, 2026-08-03
53. Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs — MedCity News, 2026-08-01
54. Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs — MedCity News, 2026-08-01